A California bill aimed at regulating kratom products, including age restrictions and labeling requirements, was shelved after disagreements among advocacy groups focused on the industry.
Kratom, derived from Southeast Asian trees, has stimulant and sedative effects, but the FDA warns against using it for medical treatment, citing serious side effects.
The proposed legislation would have required kratom products to be registered and labeled, and banned products with high concentrations of the alkaloid 7-hydroxymitragynine.
Studies suggest that 7-hydroxymitragynine could significantly contribute to kratom's addictive potential, prompting concerns from scientists about its safety and regulation.
Collection
[
|
...
]